Literature DB >> 11880101

Gene expression profiles in the Peyronie's disease plaque.

Thomas R Magee1, Ansha Qian, Jacob Rajfer, Fred C Sander, Laurence A Levine, Nestor F Gonzalez-Cadavid.   

Abstract

OBJECTIVES: To provide molecular insight into the pathophysiology of Peyronie's disease (PD), a preliminary profile of differential gene expression between the PD plaque and control tunica albuginea was obtained with DNA microarrays.
METHODS: Seven PD plaques and five control tunica albugineas were studied. cDNA specimens were prepared from RNA isolated from one calcified PD plaque and one control tissue and hybridized with the Clontech Atlas 1.2 Array. Another set of plaque and control RNA samples was hybridized with the Affymetrix GeneChip. Relative changes of greater than 2.0 defined up-regulation and down-regulation, respectively. RNA from the remaining tissues was used to determine, by reverse transcriptase-polymerase chain reaction and Western blot analysis, the expression of selected individual genes.
RESULTS: Some of up-regulated genes in the PD plaque detected by the Clontech assay were pleiotrophin, monocyte chemotactic protein 1, and early growth response protein, which are involved in osteoblast recruitment, inflammation, and fibroblast proliferation, respectively. Ubiquitin and Id-2, which are involved in tissue remodeling, were down-regulated. The Affymetrix DNA chips identified the up-regulation of elastase (involved in elastic fiber degradation) and the myofibroblast markers alpha and gamma-smooth muscle actin, desmin, and others, as well as the down-regulation of collagenase IV and transforming growth factor-beta modulators. Four of the five genes selected for reverse transcriptase-polymerase chain reaction and Western blotting confirmed the DNA microarray results.
CONCLUSIONS: In the PD tissue, the genes involved in collagen synthesis, myofibroblast differentiation, tissue remodeling, inflammation, ossification, and proteolysis are up-regulated, and the genes that inhibit some of these processes and collagenase are down-regulated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11880101     DOI: 10.1016/s0090-4295(01)01578-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  12 in total

Review 1.  Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Nat Rev Urol       Date:  2010-03-09       Impact factor: 14.432

2.  Inhibition of penile tunica albuginea myofibroblasts activity by adipose-derived stem cells.

Authors:  Hesong Jiang; Qingqiang Gao; Xiaoyan Che; Leilei Zhu; Zheng Zhang; Yun Chen; Yutian Dai
Journal:  Exp Ther Med       Date:  2017-09-21       Impact factor: 2.447

Review 3.  The Genetic Basis of Peyronie Disease: A Review.

Authors:  Amin S Herati; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2016-01-08

Review 4.  Pharmacological Management of Peyronie's Disease.

Authors:  Landon W Trost; Serap Gur; Wayne J G Hellstrom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Significant familial clustering of Peyronie's disease in close and distant relatives.

Authors:  Kristina L Allen-Brady; Michael B Christensen; Ashlynn D Sandberg; Alexander W Pastuszak
Journal:  Andrology       Date:  2022-07-13       Impact factor: 4.456

6.  The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets.

Authors:  Robert A Gelfand; Dolores Vernet; Istvan Kovanecz; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  J Sex Med       Date:  2014-12-11       Impact factor: 3.802

Review 7.  The Natural History of Peyronie's Disease.

Authors:  Fabrizio Di Maida; Gianmartin Cito; Luca Lambertini; Francesca Valastro; Girolamo Morelli; Andrea Mari; Marco Carini; Andrea Minervini; Andrea Cocci
Journal:  World J Mens Health       Date:  2020-07-08       Impact factor: 5.400

8.  Tunica albuginea allograft: a new model of LaPeyronie's disease with penile curvature and subtunical ossification.

Authors:  Ludovic Ferretti; Thomas M Fandel; Xuefeng Qiu; Haiyang Zhang; Hazem Orabi; Alex K Wu; Lia Banie; Guifang Wang; Guiting Lin; Ching-Shwun Lin; Tom F Lue
Journal:  Asian J Androl       Date:  2014 Jul-Aug       Impact factor: 3.285

Review 9.  New discoveries in the basic science understanding of Peyronie's disease.

Authors:  Mark Jalkut; Nestor Gonzalez-Cadavid; Jacob Rajfer
Journal:  Curr Urol Rep       Date:  2004-12       Impact factor: 2.862

10.  Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study.

Authors:  Gianni Paulis; Davide Barletta; Paolo Turchi; Antonio Vitarelli; Giuseppe Dachille; Andrea Fabiani; Romano Gennaro
Journal:  Res Rep Urol       Date:  2015-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.